Given the historical failure of monotherapy in treating advanced melanomas, the combined use of immunotherapy with IL-2, CTLA-4 inhibitors, adoptive T cell transfer (ATCT), and BRAF inhibitors (V600E) enhances immune responses and has become the most effective modality with very positive results for patients [36]. Here, CTLA4 is linked to melanoma.